Literature DB >> 12873485

Sub-nanomolar hMC1R agonists by end-capping of the melanocortin tetrapeptide His-D-Phe-Arg-Trp-NH(2).

L N Koikov1, F H Ebetino, M G Solinsky, D Cross-Doersen, J J Knittel.   

Abstract

Twenty three derivatives of the core fragment His(6)-D-Phe(7)-Arg(8)-Trp(9)-NH(2) end-capped with carboxylic and sulfonic acids were synthesized and evaluated at human melanocortin receptors (hMC1, hMC3, and hMC4Rs). The SAR within this series allowed us to map the hMCRs near the His(6) binding site and design a superpotent MC1R agonist, LK-184, Ph(CH(2))(3)CO-His-D-Phe-Arg-Trp-NH(2) (19) with EC(50) 0.01 nM (5 nM at MC3 and MC4Rs).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12873485     DOI: 10.1016/s0960-894x(03)00552-3

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

Authors:  Natalie M Barkey; Narges K Tafreshi; Jatinder S Josan; Channa R De Silva; Kevin N Sill; Victor J Hruby; Robert J Gillies; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2011-11-10       Impact factor: 7.446

2.  Discovery of Polypharmacological Melanocortin-3 and -4 Receptor Probes and Identification of a 100-Fold Selective nM MC3R Agonist versus a μM MC4R Partial Agonist.

Authors:  Katlyn A Fleming; Katie T Freeman; Mike D Powers; Radleigh G Santos; Ginamarie Debevec; Marc A Giulianotti; Richard A Houghten; Skye R Doering; Clemencia Pinilla; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2019-02-28       Impact factor: 7.446

3.  Discovery of Mixed Pharmacology Melanocortin-3 Agonists and Melanocortin-4 Receptor Tetrapeptide Antagonist Compounds (TACOs) Based on the Sequence Ac-Xaa1-Arg-(pI)DPhe-Xaa4-NH2.

Authors:  Skye R Doering; Katie T Freeman; Sathya M Schnell; Erica M Haslach; Marvin Dirain; Ginamarie Debevec; Phaedra Geer; Radleigh G Santos; Marc A Giulianotti; Clemencia Pinilla; Jon R Appel; Robert C Speth; Richard A Houghten; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2017-05-15       Impact factor: 7.446

4.  Development and in vivo quantitative magnetic resonance imaging of polymer micelles targeted to the melanocortin 1 receptor.

Authors:  Natalie M Barkey; Christian Preihs; Heather H Cornnell; Gary Martinez; Adam Carie; Josef Vagner; Liping Xu; Mark C Lloyd; Vincent M Lynch; Victor J Hruby; Jonathan L Sessler; Kevin N Sill; Robert J Gillies; David L Morse
Journal:  J Med Chem       Date:  2013-08-09       Impact factor: 7.446

5.  Semi-rigid tripeptide agonists of melanocortin receptors.

Authors:  Andrew R Ruwe; Leonid Koikov; Zalfa Abdel-Malek; Carrie Haskell-Luevano; Marvin L Dirain; Federico Portillo; Zhimin Xiang; Matt Wortman; James J Knittel
Journal:  Bioorg Med Chem Lett       Date:  2009-07-09       Impact factor: 2.823

6.  In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma.

Authors:  Narges K Tafreshi; Ariosto Silva; Veronica C Estrella; Timothy W McCardle; Tingan Chen; Yolaine Jeune-Smith; Mark C Lloyd; Steven A Enkemann; Keiran S M Smalley; Vernon K Sondak; Josef Vagner; David L Morse
Journal:  Mol Pharm       Date:  2013-07-08       Impact factor: 4.939

7.  Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

Authors:  Narges K Tafreshi; Xuan Huang; Valerie E Moberg; Natalie M Barkey; Vernon K Sondak; Haibin Tian; David L Morse; Josef Vagner
Journal:  Bioconjug Chem       Date:  2012-11-27       Impact factor: 4.774

8.  Development of hMC1R Selective Small Agonists for Sunless Tanning and Prevention of Genotoxicity of UV in Melanocytes.

Authors:  Leonid Koikov; Renny J Starner; Viki B Swope; Parth Upadhyay; Yuki Hashimoto; Katie T Freeman; James J Knittel; Carrie Haskell-Luevano; Zalfa A Abdel-Malek
Journal:  J Invest Dermatol       Date:  2021-02-18       Impact factor: 8.551

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.